0001193805-20-001112.txt : 20200903 0001193805-20-001112.hdr.sgml : 20200903 20200903084954 ACCESSION NUMBER: 0001193805-20-001112 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Connor Rita M CENTRAL INDEX KEY: 0001389177 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36351 FILM NUMBER: 201158345 MAIL ADDRESS: STREET 1: 49 TOBY DRIVE CITY: SUCCASUNNA STATE: NJ ZIP: 07876 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLx Pharma Inc. CENTRAL INDEX KEY: 0001497504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271707962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9 FISHERS LANE STREET 2: SUITE E CITY: SPARTA STATE: NJ ZIP: 07871 BUSINESS PHONE: (713) 842-1249 MAIL ADDRESS: STREET 1: 9 FISHERS LANE STREET 2: SUITE E CITY: SPARTA STATE: NJ ZIP: 07871 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20140313 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, LLC DATE OF NAME CHANGE: 20100726 4 1 form411577002oco_09032020.xml X0306 4 2020-09-01 0 0001497504 PLx Pharma Inc. PLXP 0001389177 O'Connor Rita M 9 FISHERS LANE SUITE E SPARTA NJ 07871 0 1 0 0 Chief Financial Officer Common Stock 2020-09-01 4 P 0 4500 3.7416 A 10850 D Common Stock 2020-09-02 4 P 0 2120 3.8333 A 12970 D The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.85, inclusive. The Reporting Person undertakes to provide the Securities and Exchange Commission, upon request, further information regarding the number of shares purchased at each separate price such shares were purchased. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.85, inclusive. The Reporting Person undertakes to provide the Securities and Exchange Commission, upon request, further information regarding the number of shares purchased at each separate price such shares were purchased. /s/ Rita M. O'Connor 2020-09-02